https://orcid.org/0000-0002-0213-311X
Figures
Abstract
Background
Acute pulmonary embolism (APE) is a major cause of death from cardiovascular disease. Right ventricular systolic dysfunction (RVD) caused by APE is closely related to a poor outcome. Early risk stratification of APE is a vital step in prognostic assessment. The objective of this study was to investigate the usefulness of computed tomographic pulmonary angiography (CTPA) measured right ventricular (RV)/ left ventricular (LV) diameter ratio by the emergency department (ED) specialists for early risk stratification of APE patients in ED.
Methods
The retrospective data of 229 APE patients were reviewed. Two ED specialists measured both RV and LV diameters on a single transverse scan perpendicular to the long axis of the heart. The patients were divided into two groups, RV/LV diameter ratio <1 and ratio >1. CTPA measured RV/LV diameter ratio were analyzed and compared with sPESI score, cardiac biomarkers such as N-Terminal Pro-B-Type Natriuretic Peptide (NT-pro-BNP), high sensitivity cardiac troponin T (hs-cTnT), and RVD measured by echocardiography (Echo).
Results
The mean age in RV/LV > 1 group was significantly higher than that of the other group (67.81±2.7 years vs. 60.68±3.2 years). Also, there were more hypertension patients (44.4% vs. 33.3%), and mean arterial pressure (MAP) was lower. A significantly higher ICU admission rate (28.05% vs. 11.61%) was shown in RV/LV >1 group, and five patients expired only in RV/LV > 1 group. RVD by Echo demonstrated the highest sensitivity, specificity, and negative predictive value (NPV) (values of 94.3%, 81.1%, 95.5%). RV/LV >1 diameter ratio by CTPA showed usefulness equivalent to cardiac biomarkers. RV/LV >1 patients’ cardiac enzymes were higher, and there were more RVD in RV/LV >1 group.
Citation: Cho S-u, Cho Y-d, Choi S-h, Yoon Y-h, Park J-h, Park S-j, et al. (2020) Assessing the severity of pulmonary embolism among patients in the emergency department: Utility of RV/LV diameter ratio. PLoS ONE 15(11): e0242340. https://doi.org/10.1371/journal.pone.0242340
Editor: Chiara Lazzeri, Azienda Ospedaliero Universitaria Careggi, ITALY
Received: July 10, 2020; Accepted: November 1, 2020; Published: November 19, 2020
Copyright: © 2020 Cho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting information files.
Funding: This study was supported by a Korea University Grant (K2008471). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interest exist.
Introduction
Acute pulmonary embolism (APE) is known as the third leading cause of death from cardiovascular disease [1]. The increased use of thrombolytic therapy and surgical embolectomy has led to a significant improvement in the prognosis of APE patients over the past decades. The results obtained from a European registry of 23,000 patients followed over 12 years showed a decrease in the all-cause mortality at 30 days, from 3.3% to 1.38% [2]. Nevertheless, the risk stratification of APE patients in the emergency department (ED) remains a challenge to physicians.
APE has a highly variable clinical course ranging from asymptomatic presentation to hemodynamic instability, right heart dysfunction, and failure, eventually leading to death [3, 4]. Massive APE patients, defined by systemic hypotension, should be considered a high-risk group, and vital therapeutic options such as thrombolysis or embolectomy need to be done [5, 6].
Early risk stratification of APE is considered a vital step in facilitating prognosis assessment and guiding therapeutic decision-making [4]. Previous studies have shown that cardiac biomarkers such as cardiac troponin and N-terminal pro-brain type natriuretic peptide (NT-pro-BNP) are effective in identifying right ventricular systolic dysfunction (RVD). Also, elevated cardiac biomarkers are closely associated with high mortality in APE patients [7, 8].
The diagnosis of PE in the ED is based on clinical probability evaluation, laboratory testing, echocardiography, and computed tomographic pulmonary angiography (CTPA) [9]. CTPA has been recommended as a first-line examination for the diagnosis of APE [4, 10].
The scoring system has been adapted for severity assessment. The pulmonary embolism severity index (PESI) score, which was introduced in 2005, had 11 routinely available clinical predictor variables with prognostic values. Based on the PESI score, the patients are categorized into five classes with 30-day mortality ranging from 1.1% to 24.5% [11, 12]. In 2010, the simplified PESI (sPESI) was developed with six of the 11 original PESI variables [13]. It was used to categorize patients into two classes: low risk, with none of the variables, and high risk, including one to six variables.
The objective of this study was to investigate the usefulness of CTPA measured right ventricular (RV)/ left ventricular (LV) diameter ratio by the ED specialists for early risk stratification of APE patients (predicting the intensive care unit (ICU) admission and in-hospital mortality) in the ED. Also, sPESI score, cardiac biomarkers such as N-Terminal Pro-B-Type Natriuretic Peptide (NT-pro-BNP), high sensitivity cardiac troponin T (hs-cTnT), RVD measured by echocardiography (Echo) were analyzed for comparison and assessment.
Materials and methods
Korea University Guro Hospital Institutional Review Board (no.2020GR0211) approved this study and waived the requirement for written informed consent because the analysis used anonymized data, which were obtained retrospectively.
This retrospective cohort study entailed a review of the electronic medical records of 314 APE patients who visited the ED from 2014 to 2017 at two tertiary hospitals located in Korea.
The charts were reviewed by two ED specialists. When conflicting data for continuous variables were presented to the chart reviewers, they used the mean value of the above-mentioned data. When the categorical variables were different, the third researcher decided which results to use after reviewing the chart.
Patients with symptoms pathognomonic for PE, such as chest pain, dyspnea, hemoptysis, and syncope, were diagnosed by the presence of thromoboemboli in at least one segmental pulmonary artery on contrast-enhanced multi-detector computed tomography.
Commercial echocardiography (Vivid E9, Vivid 7 GE Vinged Ultrasound AS, Horten, Norway) was used for evaluation of heart function. Complete two-dimensional, color flow, pulsed-wave, and continuous-wave Doppler examinations were performed according to standard techniques. RV free wall hypokinesia or akinesia demonstration by echocardiography was considered as definite evidence of RVD.
All CTPA examinations were conducted with the Siemens SOMATOM Definition edge device (Siemens Aktiengesellschaft, Munich, Germany). All CTPA images were retrospectively reviewed by 2 ED specialists. They were blinded to the clinical information, including treatments and outcomes. They measured both RV and LV diameters on a single transverse scan perpendicular to the long axis of the heart. Its definition was the largest distance between the inner aspect of the interventricular septum and the ventricular free wall (Fig 1).
NT-pro-BNP was measured with a fluorescence immunoassay using a cobas® 8000 modular analyzers (Roche Diagnostics, Mannheim, Germany). The detection limit was 18 ng/mL, and the measurement range was 18–35,000 ng/mL. NT-pro-BNP cut-off values were used, as illustrated in the textbook [14].
According to the European Society of Cardiology, hemodynamic instability was defined by a systolic blood pressure below 90 mm Hg or a need for vasopressor without other causes such as hypovolemia or septic shock condition [15].
Parameters such as NT-pro-BNP, hs-cTnT, RVD, and the RV/LV ratio via CTPA were investigated to evaluate the correlation between cardiac function and severity of APE. NT-pro-BNP levels were marked as elevated based on NT-pro-BNP cut-off values. Further, the RV and left ventricle (LV) diameter ratio were recorded based on CTPA results of RV function evaluation.
In predicting the possibility of ICU admission, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated from RV/LV diameter ratio, elevated cardiac biomarkers, and RVD by Echo.
We used SPSS software (SPSS 21.0, IBM, Chicago, USA) for statistical analysis. A P value of < 0.05 was considered to show statistical significance. Each continuous variable was expressed as a mean ± standard deviation (SD).
We conducted an ANOVA or Kruskal-Wallis test to compare the mean value in groups depending on the normality test. A Fisher exact test was used to evaluate the correlation of each. Spearman’s correlation coefficient was used to measure the degree of association between groups.
Early risk stratification time cut-off was immediately after CTPA was taken. The risk stratification needed to be done before Echo was done. The sample size of this study was calculated with the intention to conduct a prospective evaluation for future study.
Results
Between January 2014 and December 2017, 314 patients were diagnosed with APE using CTPA in the ED and 45 patients with confirmed chronic hypertension related to pulmonary thromboembolism, those transferred out of hospitals, self-discharged, or without medical records were excluded. Ultimately, 229 patients were enrolled. Patients were divided into two groups according to the RV/LV diameter ratio by CTPA (Fig 2).
Risk stratification according to RV/LV diameter ratio.
Demographic and clinical characteristics of acute pulmonary embolism patients in different RV/LV ratio groups
The mean ages of each group were 60.68±3.2 years for RV/LV diameter ratio < 1 group and 67.81±2.7 years for RV/LV diameter ratio >1 group (p < 0.001). There were more males (49.1% vs. 38.5%), and diabetes mellitus (DM) patients (32.1% vs. 24.8%) in RV/LV diameter ratio <1 group. There were more patients with systemic arterial hypertension (44.4% vs. 33.3%) in RV/LV diameter ratio >1 group. Mean arterial pressure (MAP) was recorded higher in RV/LV diameter ratio <1 group, and the mean heart rate (HR) was faster in RV/LV diameter ratio > 1 group (p < 0.001). In both groups, dyspnea and chest pain were the two most common symptoms (Table 1).
ICU admission and mortality in each RV/LV ratio group
Significantly higher ICU admission rate (28.05% vs. 11.61%) was shown in RV/LV diameter ratio >1 group (p<0.001) and five patients expired only in RV/LV diameter ratio > 1 group (p<0.001) (Table 2).
Performance of RV/LV diameter ratio >1, elevated NT-pro-BNP, RVD detected by Echo, and elevated hs-cTnT for predicting ICU admission
RVD by Echo demonstrated the highest sensitivity, specificity and NPV (values of 94.3, 81.1, 95.5). RV/LV >1 diameter ratio by CTPA showed usefulness equivalent to cardiac biomarkers (NT-pro-BNP, hs-cTnT) (p < 0.001) (Table 3).
Composition of patients in each parameter
Ten patients (8.9%) with elevated NT-pro BNP were in RV/LV diameter ratio <1 group and 57 patients (48.7%) were with elevated NT-pro BNP in RV/LV diameter ratio >1 group (P<0.001) (Fig 3).
(P = 0.000).
There were 8 patients (10.5%) with RVD detected by Echo in RV/LV diameter ratio <1 group and 82 patients (70.1%) in >1 group (p<0.001) (Fig 4). Result of elevated hs-cTnT patients’ composition in RV/LV diameter ratio >1 group were similar. It showed 23 patients (19.7%) in RV/LV diameter ratio >1 group compared to 6 patients (5.4%) in RV/LV diameter ratio < 1 group (p = 0.001) (Fig 5).
(P< 0.001).
(P = 0.001).
sPESI score distribution in each RV/LV ratio group
In contrast to the RV/LV diameter ratio <1 group, RV/LV diameter ratio >1 group showed significantly more number of scores 2 and 3 patients. Also, there were not any score 4 and 5 patients in RV/LV diameter ratio <1 group, whereas RV/LV diameter ratio >1 group included 4 and 5 score patients, one each. sPESI score showed a significant positive correlation with RV/LV diameter ratio groups (R = 0.863, p<0.001) (Fig 6).
Discussion
Several studies have shown reliable evidence suggesting that the prognosis of APE patients is influenced by hemodynamic status, right ventricular dysfunction with or without myocardial injury, and other clinical features [16, 17]. Based on our study results, older patients tend to manifest a higher risk than younger patients, and a lower MAP was observed among RV/LV diameter ratio >1 group. It is possibly attributed to underlying comorbidity in older patients, and groups with elevated risks exhibit unstable vital signs. In-hospital mortality and ICU admission rates were significantly higher in the RV/LV diameter ratio >1 group; there was no mortality in the RV/LVdiameter ratio >1 group. Furthermore, there seem to be strong correlations between RV/LV diameter ratio by CTPA and other parameters such as cardiac biomarkers, Echo findings, and sPESI scores in risk stratification. This study showed that CTPA is used not only as a diagnostic tool but also to assess the severity of APE and the RV function, as well as predict the prognosis such as ICU admission and mortality.
CTPA has been an effective tool in APE diagnosis as well as in the process of the clinical decision making of therapeutic strategy and risk stratification [18]. Echo can be used to evaluate the overall function of the heart, especially the assessment of the RV. It can be used to detect RVD and facilitate the diagnosis of APE as well as risk stratification [19, 20]. Nonetheless, the precise role of echocardiographic RVD in APE diagnosis or risk stratification has yet to be demonstrated [21]. RV dilation based on CTPA result as a measure of RVD has shown a strong correlation with echocardiographic parameter and to predict a higher 30–day mortality risk [22, 23].
RV/LV diameter ratio measurement on CTPA has an advantage over other tests such as Echo. It eliminates the unnecessary additional testing for RV evaluation in addition to the diagnostic testing for APE confirmation.
This study has a number of limitations. The main limitation is that this is not a randomized controlled study and may have a selection bias of subjects. Also, the timing of blood sampling from cardiac biomarkers may be different for each patient. And, other possible signs of RVD from CTPA were not considered. Finally, other echocardiographic measurements such as RV FAC, RV diameter, RA diameter, LV diameter, and TAPSE were not analyzed in this study. However, such parameters can be accepted with the intention of creating a hypothesis that would be analyzed prospectively in our next study.
The accuracy of RV/LV diameter ratio measurement on CTPA by non-radiologists has been studied, and the accuracy and reproducibility have been proven [24]. This is relevant for emergency medicine specialists in the ED. Most of the APE patients are initially diagnosed and risk assessed in the ED, and their outcomes and prognosis may depend on the initial assessment.
Conclusion
Simple measurement of RV/LV diameter ratio by ED specialist would be a help to the clinicians in identifying and stratifying the risk of the APE patients presenting in the ED.
Acknowledgments
I would like to express my gratitude to my colleagues who helped and supported during the writing of this manuscript and special thanks to all peer reviewers and editors for their sincere concerns and suggestions.
References
- 1. Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis, and non thrombotic pulmonary embolism. Exp Clin Cardiol 2013; 18:129–138.
- 2. Stein PD, Beemath A, Matta F, Weg JG, Yusen RD, Hales CA, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med 2007; 120:871–879. pmid:17904458
- 3. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21: 1301–1336. pmid:10952823
- 4. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS), Eur Heart J 2020; 41(4):543–603.
- 5. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S–428S. pmid:15383479
- 6. Tokyo CCU Network Scientific Committee. Latest management and outcomes of major pulmonary embolism in the cardiovascular disease early transport system: Tokyo CCU Network. Circ J 2010;74:289–293. pmid:20019409
- 7. Tulevski II, ten Wolde M, van Veldhuisen DJ, Mulder JW, van der Wall EE, Buller HR, et al. Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. Int J Cardiol 2007; 116: 161–166. pmid:16814410
- 8. Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: A systematic review. Eur Heart J 2008; 29: 1569–1577. pmid:18495689
- 9. Van Belle A, Büller HR, Huisman MV, Huisman PM, Kaasjager K, Kamphuisen PW, et al. Christopher Study Investigators. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295:172–179. pmid:16403929
- 10. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35:3033–3069,3069a. pmid:25173341
- 11. Schoepf UJ, Costello P. CT angiography for diagnosis of pulmonary embolism: State of the art. Radiology 2004; 230: 329–337. pmid:14752178
- 12. Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Eng J Med 1980; 302:1109–1117. pmid:7366635
- 13. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonaryembolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123:1788–1830 pmid:21422387
- 14. Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, et al. RIETE Investigators: Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170:1383–1389. pmid:20696966
- 15.
Tintinalli JE, Stapczynski JS, MA OJ, Cline DM, Meckler GD, Yealy DM. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. 9th ed. New York: McGraw Hill, 2019:369.
- 16. Jiménez D, de Miguel-Díez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, et al. RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE registry. J Am Coll Cardiol 2016; 67:162–170. pmid:26791063
- 17. Klok Frederikus A, Mos Ingr CM, Huisman Menno V: Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism-A systemic review and meta-analysis. Am J Resp Crit Care Med 2008, 178:425–430. pmid:18556626
- 18. West J, Goodacre S, Sampson F: The value of clinical features in the diagnosis of acute pulmonary embolism: systemic review and meta-analysis. QJM-An International Journal of Medicine 2007; 100:763–769. pmid:18089542
- 19. Osman AM, Abdeldayem EH. Value of CT pulmonary angiography predict short-term outcome inpatient with pulmonary embolism. Int J Cardiovasc Imaging 2018; 34:975–983. pmid:29349525
- 20. Coutance G, Cauderlier E, Ehtisham J, Hamon M, Hamon M. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis. Critical Care 2011; 2:R103. pmid:21443777
- 21. Barrios D, Morillo R, Lobo JL, Nieto R, Jaureguizar A, Portillo AK, et al. Assessment of right ventricular function in acute pulmonary embolism. Am Heart J 2017; 185:123–129. pmid:28267465
- 22. Ozsu S, Karaman K, Mentese A, Ozsu A, Karahan SC, Durmus I, et al. Combined risk stratification with computerized tomography /echocardiography and biomarkers in patients with normotensive pulmonary embolism. Thrombosis research. 2010;126(6):486–492. pmid:20920821
- 23. Becattini C, Agnelli G, Germini F, Vedovati MC. Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. The European respiratory journal. 2014;43(6):1678–1690. pmid:24603813
- 24. Yvonne ME, Lucia JM, Inge CM, Menno V, Frederikus A. Accuracy and Reproducibility of CT Right-To-Left Ventricular Diameter Measurement in Patients With Acute Pulmonary Embolism. PLos One. 2017;12: e0188862. pmid:29182657